Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (585)	4/8/1999 10:36:00 PM
From: scaram(o)uche	Respond to of 4974

Chuckle. As you know, I'm also watching H3 receptor agonists and their potential for this indication. IMO, there will be a lot of market to go around for good anti-insomnia drugs.

To: Miljenko Zuanic who wrote (585)	4/8/1999 10:49:00 PM
From: LLCF	Read Replies (2) \| Respond to of 4974

< NBI-34060 is Sonata (zaleplon) sister (or back-up) compound, So does this mean that AHP won't push to get the compound going??? Seems unfair. I noticed that the press release stated "with improved side-effect profile relative to currently available drugs" does that include Sonata... or do they mean GABA(A) in general... also, if these drugs are very similar shouldn't it "fly to approval quickly"???? DAK PS... are you saying this compound is still "unpartnered"?